Favorable outcomes with reduced steroid use in juvenile dermatomyositis.
Amir B OrandiLampros FotisJamie LaiHallie MorrisAndrew J WhiteAnthony R FrenchKevin W BaszisPublished in: Pediatric rheumatology online journal (2021)
Current accepted treatment paradigms for Juvenile Dermatomyositis include oral glucocorticoids beginning at 2 mg/kg/day and reduced over a prolonged time period. However, our results suggest that treatment using reduced doses and duration with early use of steroid-sparing agents is comparably effective in achieving favorable outcomes in Juvenile Dermatomyositis.